Skip to content

Study · Animal study (in vivo) · mouse · 2018

8 results

Control of appetite, blood glucose, and blood pressure during melanocortin-4 receptor activation in normoglycemic and diabetic NPY-deficient mice.

da Silva AA, Freeman JN, Hall JE, do Carmo JM

American journal of physiology. Regulatory, integrative and comparative physiology20 Dec 2017Cited by 7 (Europe PMC)

PMID29351428 (opens in a new tab)PMCIDPMC5966815 (opens in a new tab)DOI10.1152/ajpregu.00293.2017 (opens in a new tab)PepBankPUB-29351428
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    Chronic MTII infusion reduced food intake in both wild-type and NPY-deficient mice.

    In plain wordsIn mice, MTII infusion lowered food intake in both normal and NPY-deficient mice.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood intake during MTII infusion
    Study

    mousen: not reported in source

    Wild-type and NPY-deficient mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    120 μg/kg/day · intravenous infusion · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    Chronic MTII infusion reduced food intake in both groups
    2 context sentences
    Summary · context
    Wild-type (WT) and NPY-deficient (NPY-/-) mice were implanted with telemetry probes for measuring mean arterial pressure (MAP) and heart rate (HR) 24 h/day.
    Summary · context
    After the mice recovered from surgery and stable baseline measurements, the MC3/4R agonist melanotan II (MTII, 120 μg·kg-1·day-1 iv) was infused for 7 days followed by a recovery period.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    Chronic MTII infusion caused transient increases in mean arterial pressure in wild-type mice.

    In plain wordsIn normal mice, MTII infusion briefly raised blood pressure.

    Peptide
    Melanotan II
    Outcome
    IncreaseMean arterial pressure during MTII infusion in wild-type mice
    Study

    mousen: not reported in source

    Wild-type mice
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    120 μg/kg/day · intravenous infusion · 7 daysAs given in this study (mouse).

    Measurements

    MAP peak increase
    11 mmHg
    wild-type mice

    Source sentences

    Summary
    while causing transient increases in MAP and HR only in WT mice (peaks of 11 ± 3 mmHg and 126 ± 13 beats/min).
    2 context sentences
    Summary · context
    Wild-type (WT) and NPY-deficient (NPY-/-) mice were implanted with telemetry probes for measuring mean arterial pressure (MAP) and heart rate (HR) 24 h/day.
    Summary · context
    After the mice recovered from surgery and stable baseline measurements, the MC3/4R agonist melanotan II (MTII, 120 μg·kg-1·day-1 iv) was infused for 7 days followed by a recovery period.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    Chronic MTII infusion caused transient increases in heart rate in wild-type mice.

    In plain wordsIn normal mice, MTII infusion briefly raised heart rate.

    Peptide
    Melanotan II
    Outcome
    IncreaseHeart rate during MTII infusion in wild-type mice
    Study

    mousen: not reported in source

    Wild-type mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    120 μg/kg/day · intravenous infusion · 7 daysAs given in this study (mouse).

    Measurements

    Heart rate peak increase
    126 beats/min
    wild-type mice

    Source sentences

    Summary
    while causing transient increases in MAP and HR only in WT mice (peaks of 11 ± 3 mmHg and 126 ± 13 beats/min).
    2 context sentences
    Summary · context
    Wild-type (WT) and NPY-deficient (NPY-/-) mice were implanted with telemetry probes for measuring mean arterial pressure (MAP) and heart rate (HR) 24 h/day.
    Summary · context
    After the mice recovered from surgery and stable baseline measurements, the MC3/4R agonist melanotan II (MTII, 120 μg·kg-1·day-1 iv) was infused for 7 days followed by a recovery period.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    Chronic MTII infusion did not increase mean arterial pressure in NPY-deficient mice.

    In plain wordsIn NPY-deficient mice, MTII infusion did not raise blood pressure.

    Peptide
    Melanotan II
    Outcome
    No significant changeMean arterial pressure during MTII infusion in NPY-deficient mice
    Study

    mousen: not reported in source

    NPY-deficient mice
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    120 μg/kg/day · intravenous infusion · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    while causing transient increases in MAP and HR only in WT mice (peaks of 11 ± 3 mmHg and 126 ± 13 beats/min).
    2 context sentences
    Summary · context
    Wild-type (WT) and NPY-deficient (NPY-/-) mice were implanted with telemetry probes for measuring mean arterial pressure (MAP) and heart rate (HR) 24 h/day.
    Summary · context
    After the mice recovered from surgery and stable baseline measurements, the MC3/4R agonist melanotan II (MTII, 120 μg·kg-1·day-1 iv) was infused for 7 days followed by a recovery period.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    Chronic MTII infusion did not increase heart rate in NPY-deficient mice.

    In plain wordsIn NPY-deficient mice, MTII infusion did not raise heart rate.

    Peptide
    Melanotan II
    Outcome
    No significant changeHeart rate during MTII infusion in NPY-deficient mice
    Study

    mousen: not reported in source

    NPY-deficient mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    120 μg/kg/day · intravenous infusion · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    while causing transient increases in MAP and HR only in WT mice (peaks of 11 ± 3 mmHg and 126 ± 13 beats/min).
    2 context sentences
    Summary · context
    Wild-type (WT) and NPY-deficient (NPY-/-) mice were implanted with telemetry probes for measuring mean arterial pressure (MAP) and heart rate (HR) 24 h/day.
    Summary · context
    After the mice recovered from surgery and stable baseline measurements, the MC3/4R agonist melanotan II (MTII, 120 μg·kg-1·day-1 iv) was infused for 7 days followed by a recovery period.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    Chronic MTII treatment did not reverse the hyperphagia in streptozotocin-induced diabetic wild-type and NPY-deficient mice.

    In plain wordsIn diabetic mice, MTII treatment did not reverse increased eating.

    Peptide
    Melanotan II
    Outcome
    No significant changeHyperphagia in STZ-induced diabetes
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetic wild-type and NPY-deficient mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    120 μg/kg/day · intravenous infusion · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    In WT and NPY-/- mice, STZ-induced diabetes led to similar hyperphagia, hyperglycemia, and weight loss, which were not reversed by chronic MTII treatment.
    2 context sentences
    Summary · context
    Wild-type (WT) and NPY-deficient (NPY-/-) mice were implanted with telemetry probes for measuring mean arterial pressure (MAP) and heart rate (HR) 24 h/day.
    Summary · context
    After the mice recovered from surgery and stable baseline measurements, the MC3/4R agonist melanotan II (MTII, 120 μg·kg-1·day-1 iv) was infused for 7 days followed by a recovery period.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    Chronic MTII treatment did not reverse the hyperglycemia in streptozotocin-induced diabetic wild-type and NPY-deficient mice.

    In plain wordsIn diabetic mice, MTII treatment did not lower high blood sugar.

    Peptide
    Melanotan II
    Outcome
    No significant changeHyperglycemia in STZ-induced diabetes
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetic wild-type and NPY-deficient mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 μg/kg/day · intravenous infusion · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    In WT and NPY-/- mice, STZ-induced diabetes led to similar hyperphagia, hyperglycemia, and weight loss, which were not reversed by chronic MTII treatment.
    2 context sentences
    Summary · context
    Wild-type (WT) and NPY-deficient (NPY-/-) mice were implanted with telemetry probes for measuring mean arterial pressure (MAP) and heart rate (HR) 24 h/day.
    Summary · context
    After the mice recovered from surgery and stable baseline measurements, the MC3/4R agonist melanotan II (MTII, 120 μg·kg-1·day-1 iv) was infused for 7 days followed by a recovery period.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    Chronic MTII treatment did not reverse the weight loss in streptozotocin-induced diabetic wild-type and NPY-deficient mice.

    In plain wordsIn diabetic mice, MTII treatment did not reverse weight loss.

    Peptide
    Melanotan II
    Outcome
    No significant changeWeight loss in STZ-induced diabetes
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetic wild-type and NPY-deficient mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    120 μg/kg/day · intravenous infusion · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    In WT and NPY-/- mice, STZ-induced diabetes led to similar hyperphagia, hyperglycemia, and weight loss, which were not reversed by chronic MTII treatment.
    2 context sentences
    Summary · context
    Wild-type (WT) and NPY-deficient (NPY-/-) mice were implanted with telemetry probes for measuring mean arterial pressure (MAP) and heart rate (HR) 24 h/day.
    Summary · context
    After the mice recovered from surgery and stable baseline measurements, the MC3/4R agonist melanotan II (MTII, 120 μg·kg-1·day-1 iv) was infused for 7 days followed by a recovery period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.